Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis

Bartosińska, Joanna; Zakrzewska, Ewelina; Purkot, Joanna; Michalak-Stoma, Anna; Kowal, Małgorzata; Krasowska, Dorota; Chodorowska, Grażyna; Giannopoulos, Krzysztof

doi:10.5114/ada.2018.75609

Cited by 21 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our present study, the circulating sNRP-1 was significantly higher in psoriatic patients in comparison to the controls, whereas in one of our earlier studies, the expression of NRP-1 mRNA in peripheral blood mononuclear cells (PBMCs) was significantly downregulated in psoriatic patients, both with and without arthritis [21]. Therefore, the increased sNRP-1 concentrations observed in our psoriatic patients could be regarded as a negative feedback mechanism in the process of neovascularization, on the one hand, but, on the other hand, they could also be seen as an immune tolerance compromising factor.…”

Section: Discussioncontrasting

confidence: 52%

“…The soluble form of PD-1, however, acts as a decoy receptor able to bind and neutralize PD-1/PDL1 [4, 5]. In our recent studies we have found that both the expression of PDCD1 mRNA in peripheral blood mononuclear cells [20] and the expression of PD-1 protein on CD4+ and CD8+ T cells were significantly decreased in psoriatic patients both with and without arthritis [21]. Thus, the compromised PD-1 function on CD4 + and CD8+ T cells might indicate inappropriate activation status and suggest dysregulation of the immune suppression mechanisms, which may lead to abnormal, persistent T cell activation and cytokine production in psoriasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Bartosińska

Michalak-Stoma

Kowal

et al. 2019

pdia

Self Cite

View full text Add to dashboard Cite

A b s t r a c tIntroduction: Circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) take part in modulating immune tolerance causing disturbances in the molecular mechanisms responsible for maintenance of balance between effector and regulatory components of the immune system. Since their cell-surface expression levels were found to be changed in lesional and/or non-lesional skin of psoriatic patients, analysis of soluble PD-1, NRP-1 and HLA-G concentrations sheds more light on their role in detecting unbalanced immune tolerance in psoriasis. Aim: To assess soluble PD-1, NRP-1 and HLA-G concentrations in psoriasis. Material and methods: The study included 57 psoriatic patients and 29 controls. Duration of psoriasis was in the range 1 to 55 years; the median was 19 years. The plasma concentrations of soluble HLA-G (sHLA-G), soluble NRP-1 (sNRP-1) and soluble PD-1 (sPD-1) were examined using the ELISA method. Severity of the skin lesions was assessed by means of Psoriasis Area Severity Index (PASI), body surface area (BSA) and Physician Global Assessment (PGA). Results: Psoriasis Area Severity Index in the studied group was in the range 3 to 43; the median was 12. Body surface area was in the range 2-75%; the median was 15%. The median value of PGA was 3. Soluble NRP concentration was significantly higher in the psoriatic patients (median: 1.59 pg/ml; range: 0.67-2.62 pg/ml) than in the control group (median: 1.35 pg/ml; range: 0.05-2.61 pg/ml) (p = 0.010). Soluble PD-1 and sHLA-G concentrations were not significantly different between the studied and control groups (p = 0.094 and p = 0.482, respectively). Conclusions: Increased concentrations of sNRP-1 and unchanged values of sHLA-G and sPD-1 concentrations may be indicative of impaired immune tolerance mechanisms in psoriasis.

show abstract

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Bartosińska

Michalak-Stoma

Kowal

et al. 2019

pdia

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, PD-1 expression is absent on OA synovial T cells, suggesting its expression may be involved in IA pathogenesis rather than merely a consequence of inflammation [ 70 ]. Within the periphery, a decrease in the percentage of circulating CD4 + and CD8 + PD-1 + cells in the blood of PsA and RA patients, respectively, has also been reported [ 71 , 72 ]. In the context of myeloid cells, PD-L1 is expressed on synovial fluid CD1c + dendritic cells [ 68 ], in addition to synovial fluid macrophages [ 67 ].…”

Section: Introductionmentioning

confidence: 99%

The PD-1:PD-L1 axis in Inflammatory Arthritis

et al. 2021

View full text Add to dashboard Cite

The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the programmed cell death protein 1 (PD-1). Blockade of PD-1 or its ligand PD-L1 has proven successful in the treatment of a wide variety of cancers, therefore highlighting an important role for this pathway in anti-tumour immune responses. However, a caveat of PD-1 therapy and boosting anti-tumour immune responses is the development of self-reactive T cells which can lead to the induction of various autoimmune or inflammatory diseases, referred to as immune- related adverse events (irAEs). The emergence of rheumatological irAEs such as Inflammatory Arthritis (IA) in recent years has highlighted the importance of PD-1 in maintaining self-tolerance. Furthermore, the emergence of rheumatology related irAEs raises an important question as to how defects in this pathway can contribute to spontaneous rheumatological disease. In this review, we describe the biological distribution, function and regulation of the PD-1 pathway, its potential role in IA and irAE related IA.

show abstract

“…Early diagnosis and effective treatment protect patients from complications and severe consequences of the musculoskeletal system. In order to understand the exact etiopathogenesis of this disease, its early detection and effective treatment, various biomarkers specific to this disease are investigated [1,[4][5][6][7][8]. According to the National Institutes of Health Biomarkers Definitions Working Group, a biomarker is "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention" [9].…”

Section: Introductionmentioning

confidence: 99%

The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients

Waszczykowski

Bednarski

Lesiak

et al. 2020

pdia

View full text Add to dashboard Cite

Introduction: Effective treatment in psoriatic arthritis (PsA) patients can protect them from severe musculoskeletal complications. For appropriate monitoring of anti-tumour necrosis factor α (anti-TNF-α) treatment in PsA, specific biomarkers are needed. Aim: To investigate whether biological treatment with anti-TNF-α (etanercept 50 mg once a week subcutaneously) affects the activity of selected mediators of inflammation and destruction of articular cartilage: interleukin-6 (IL-6), interleukin-18 (IL-18), matrix metalloproteinases 1 and 3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), human cartilage glycoprotein (YKL-40) in serum of patients with PsA. Material and methods: The study included 25 patients with PsA. The concentration of IL-6, IL-18, MMP-1, MMP-3, COMP and YKL-40 in serum was determined before, and 6 and 12 weeks after the beginning of anti-TNF-α treatment. Clinical severity of the disease according to the Body Surface Area, Psoriasis Area and Severity Index and Dermatology Life Quality Index as well as tender and swollen joint count (TJC, SJC) were also evaluated. Results: The study disclosed a statistically significant reduction in the serum concentration of IL-6, MMP-1 and YKL-40 in PsA patients after 6 and 12 weeks from the beginning of anti-TNF-α treatment (p = 0.00018 for IL-6; p = 0.01242 for MMP-1; p = 0.03263 for YKL-40). Conclusions: IL-6, MMP-1 and YKL-40 may be useful for monitoring the effectiveness of anti-TNF-α treatment.

show abstract

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis

Cited by 21 publications

References 22 publications

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients

The PD-1:PD-L1 axis in Inflammatory Arthritis

The influence of tumour necrosis factor α inhibitors treatment – etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients

Contact Info

Product

Resources

About